Animesh Barua

Dr. Animesh Barua

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
ABAnimesh Barua
Animesh Barua
PBPincas Bitterman
Pincas Bitterman
JAJacques Abramowicz
Jacques Abramowicz
ADAngela L. Dirks
Angela L. Dirks
JBJanice M. Bahr
Janice M. Bahr
JLJudith L. Luborsky
Judith L. Luborsky

22 December 2010 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
KPKrishna Penumatsa
Krishna Penumatsa
SESeby L Edassery
Seby L Edassery
ABAnimesh Barua
Animesh Barua
MBMichael J Bradaric
Michael J Bradaric
JLJudith L Luborsky
Judith L Luborsky
Background: We showed there are specific ALDH1 autoantibodies in ovarian autoimmune disease and ovarian cancer, suggesting a role for ALDH1 in ovarian pathology. However, there is little information on the ovarian expression of ALDH1. Therefore, we compared ALDH1 expression in normal ovary and benign and malignant ovarian tumors to determine if ALDH1 expression is altered in ovarian cancer. Since there is also recent interest in ALDH1 as a cancer stem cell (CSC) marker, we assessed co-expression of ALDH1 with CSC markers in order to determine if ALDH1 is a potential CSC marker in ovarian cancer. Methods: mRNA and protein expression were compared in normal human ovary and serous ovarian tumors using quantitative Reverse-Transcriptase PCR, Western blot (WB) and semi-quantitative immunohistochemistry (IHC). ALDH1 enzyme activity was confirmed in primary ovarian cells by flow cytometry (FC) using ALDEFLUOR assay. Results: ALDH1 mRNA expression was significantly reduced (p < 0.01; n = 5) in malignant tumors compared to normal ovaries and benign tumors. The proportion of ALDH1+ cells was significantly lower in malignant tumors (17.1 ± 7.61%; n = 5) compared to normal ovaries (37.4 ± 5.4%; p < 0.01; n = 5) and benign tumors (31.03 ± 6.68%; p < 0.05; n = 5). ALDH1+ cells occurred in the stroma and surface epithelium in normal ovary and benign tumors, although surface epithelial expression varied more in benign tumors. Localization of ALDH1 was heterogeneous in malignant tumor cells and little ALDH1 expression occurred in poorly differentiated malignant tumors. In benign tumors the distribution of ALDH1 had features of both normal ovary and malignant tumors. ALDH1 protein expression assessed by IHC, WB and FC was positively correlated (p < 0.01). ALDH1 did not appear to be co-expressed with the CSC markers CD44, CD117 and CD133 by IHC. Conclusions: Total ALDH1 expression is significantly reduced in malignant ovarian tumors while it is relatively unchanged in benign tumors compared to normal ovary. Thus, ALDH1 expression in the ovary does not appear to be similar to breast, lung or colon cancer suggesting possible functional differences in these cancers. Significance: These observations suggest that reduced ALDH1 expression is associated with malignant transformation in ovarian cancer and provides a basis for further study of the mechanism of ALDH1 in this process.

1 February 2012 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
PDF file
AYAparna Yellapa
Aparna Yellapa
JBJanice M. Bahr
Janice M. Bahr
PBPincas Bitterman
Pincas Bitterman
JAJacques Abramowicz
Jacques Abramowicz
SESeby L. Edassery
Seby L. Edassery
ABAnimesh Barua
Animesh Barua
Objective Tumor-associated neoangiogenesis (TAN) is an early event in ovarian tumor development. Interleukin 16 (IL-16) is a proangiogenic cytokine that stimulates production of neoangiogenic factors. The goal of this study was to determine the association of IL-16 with tumor development and ovarian TAN in laying hens, an animal model of spontaneous ovarian cancer (OVCA). Methods Sera and ovarian tissues from 3-year-old laying hens were collected and processed for histopathologic, immunoassay, immunohistochemistry, immunoblotting, and molecular biological studies to determine the tissue expression and serum levels of IL-16. Samples were divided into 3 groups based on the diagnosis of the histopathologic ovarian tissue examination, namely, normal (healthy control, n = 81), early (n = 23 including 11 with microscopic OVCA), and late stages (n = 16) of OVCA. Results Serum levels of IL-16 were significantly higher in hens with microscopic, early, and late stages of OVCA than normal hens (P < 0.0001). The frequencies of IL-16+cells in tumor-bearing ovaries were significantly higher than normal hens (P < 0.05). The expression of IL-16 protein and mRNA were stronger in tumor-bearing ovaries than normal ovaries. In addition to ovarian stroma, IL-16 was also expressed by the epithelial cells of the tumor in OVCA hens. Differences in serum levels and ovarian IL-16 expression were not significant among different histological subtypes of OVCA including serous, endometrioid, and mucinous. Similar to the serum levels and ovarian expression of IL-16, the densities of neoangiogenic microvessels were significantly higher in hens with tumor-bearing ovaries than normal hens. Conclusions The results of the study suggest that changes in serum levels of IL-16 are associated with tumor development and TAN. Thus, serum IL-16 levels may be an indicator of ovarian TAN at the early stage of OVCA.

1 March 2014 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
AYAparna Yellapa
Aparna Yellapa
PBPincas Bitterman
Pincas Bitterman
SSSameer Sharma
Sameer Sharma
AGAlfred S. Guirguis
Alfred S. Guirguis
JBJanice M. Bahr
Janice M. Bahr
ABAnimesh Barua
Animesh Barua

1 April 2009 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
ABAnimesh Barua
Animesh Barua
SESeby L. Edassery
Seby L. Edassery
PBPincas Bitterman
Pincas Bitterman
JAJacques Abramowicz
Jacques Abramowicz
ADAngela L. Dirks
Angela L. Dirks
JLJudith L. Luborsky
Judith L. Luborsky

5 November 2013 in American Journal of Reproductive Immunology
Verified
Journal Article
Closed access
PDF file
ABAnimesh Barua
Animesh Barua
MBMichael J. Bradaric
Michael J. Bradaric
PBPincas Bitterman
Pincas Bitterman
JAJacques Abramowicz
Jacques Abramowicz
SSSameer Sharma
Sameer Sharma
JBJanice M. Bahr
Janice M. Bahr